Patients and methods
With the exception of patient No. 5, the conditioning included Ara-C (36 g/m 2 over 6 days) followed by fractionated TBI (10 Gy). Patient No. 5 received CY 60 mg/kg/day GVHD remains a major contributor to both morbidity and for 2 days followed by fractionated TBI (12 Gy). As GVHD mortality in pediatric as well as in adult stem cell transplanprophylaxis they all received MTX 15 mg/m 2 i.v. on day tation. 1 Although the risk for both acute and chronic GVHD ϩ1 post-transplant followed by 10 mg/m 2 i.v. on days ϩ3, is lower among pediatric patients it appears substantially ϩ6 and ϩ11, respectively. Additionally, they were on daily higher among those receiving stem cells from an cyclosporine (for doses see Table 1 ) from day Ϫ1 onwards. unrelated donor. 2 Despite recent developments 3-5 glucocorticoids have retained their role as the cornerstone of the initial treatment Acute GVHD of acute GVHD among pediatric patients. 6, 7 This is regardless of their widely acknowledged and substantial shortAcute cutaneous GVHD was diagnosed and staged on the and long-term side-effects which are also encountered in basis of clinical criteria alone and in the GI tract of patient relation to short courses of treatment. 8 The question of No. 2 also employing histopathological criteria. whether it is possible to intervene effectively in the process Patients with mild (skin stage ϩ to ϩϩ) acute GVHD of GVHD in its early stages with other, and possibly less were considered eligible for treatment with very low-dose toxic, modalities of treatment currently remains unsettled.
MTX. Patient No. 2 concomitantly had anorexia and nausea In our unit, we have aimed at initiating the therapy of protogether with changes of histopathological grades 1-2 in gressive acute GVHD at its early stages of cutaneous sympthe esophagus, duodenum and colon. toms with very low-dose MTX in the hope of decreasing A prompt decrease in the activity of the cutaneous sympthe activity of the process or even halting it altogether. toms of GVHD followed by clearance of the rash altogether We report a series of five pediatric recipients of unrelated were considered as a response to treatment. The dosage of grafts with progressive cutaneous GVHD successfully cyclosporine was kept at a level differing no more than treated with very low-dose methotrexate.
Ϯ10% from that at the initiation of MTX and the respective levels of CSA are given in Table 1 . No other treatment for acute GVHD was administered and none of the patients in the study group received treatment with glucocorticoids. During the study period a total of 12 marrow transplants from unrelated donors were performed. Signs and symptoms of acute GVHD were encountered in 11/12 with a 76 
Results
form of increased susceptibility to infections, impaired wound healing, risk for osteonecrosis etc. In contrast, throughout the years of its use in prophylaxis The onset of symptoms, the initial stage of GVHD, days with very low-dose MTX, the respective doses of MTX, and despite its potent effects on cell-mediated immunity, the toxicity of low-dose MTX has remained low.
3 duration of symptoms as well as the level of CsA during treatment with MTX and the next 7 days following the last Our clinical experience suggests that very low-dose methotrexate may constitute an alternative to glucocortidose of MTX are given in Table 1 .
Cutaneous signs of acute GVHD fully subsided within a coids, with potentially less toxicity, in the initial treatment of stage ϩ to ϩϩ, cutaneous GVHD among pediatric mean of eight (range 2-17) days since the last dose of MTX. The GI symptoms of patient No. 2 disappeared conrecipients of stem cell grafts. In addition, it may give an indication for further studies on the role of treatment with comitantly with those involving the skin and the GI tract was not rebiopsied. Thereafter all patients remained free of very low doses of MTX in the prevention of the chronic forms of GVHD. any cutaneous or gastrointestinal signs of acute GVHD. None of the patients ever demonstrated signs of acute hepatic GVHD.
